Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Free Cash Flow (2019 - 2025)

Eton Pharmaceuticals' Free Cash Flow history spans 7 years, with the latest figure at $11.7 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 297.76% year-over-year to $11.7 million; the TTM value through Sep 2025 reached $21.0 million, up 897.34%, while the annual FY2024 figure was $943000.0, 86.16% down from the prior year.
  • Free Cash Flow for Q3 2025 was $11.7 million at Eton Pharmaceuticals, up from $8.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $11.7 million in Q3 2025 and bottomed at -$5.1 million in Q4 2021.
  • The 5-year median for Free Cash Flow is $1.2 million (2022), against an average of $1.6 million.
  • The largest annual shift saw Free Cash Flow soared 763.96% in 2022 before it crashed 300.78% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$5.1 million in 2021, then surged by 155.22% to $2.8 million in 2022, then crashed by 86.32% to $387000.0 in 2023, then plummeted by 300.78% to -$777000.0 in 2024, then skyrocketed by 1611.2% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Free Cash Flow are $11.7 million (Q3 2025), $8.0 million (Q2 2025), and $2.1 million (Q1 2025).